BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 29912167)

  • 1. Neutralizing Antibody-Based Prevention of Cell-Associated HIV-1 Infection.
    Parsons MS; Le Grand R; Kent SJ
    Viruses; 2018 Jun; 10(6):. PubMed ID: 29912167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
    Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
    J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection.
    Saunders KO; Wang L; Joyce MG; Yang ZY; Balazs AB; Cheng C; Ko SY; Kong WP; Rudicell RS; Georgiev IS; Duan L; Foulds KE; Donaldson M; Xu L; Schmidt SD; Todd JP; Baltimore D; Roederer M; Haase AT; Kwong PD; Rao SS; Mascola JR; Nabel GJ
    J Virol; 2015 Aug; 89(16):8334-45. PubMed ID: 26041300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Report of the Cent Gardes HIV Vaccine Conference: The B-cell Response to HIV. Part 1: Broadly Neutralizing Antibodies Fondation Mérieux Conference Center, Veyrier du Lac, France, 5-7 November 2012.
    Girard MP; Picot V; Longuet C; Nabel GJ
    Vaccine; 2013 Jun; 31(29):2979-83. PubMed ID: 23499518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
    Li H; Zony C; Chen P; Chen BK
    J Virol; 2017 May; 91(9):. PubMed ID: 28148796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-Dependent.
    Reh L; Magnus C; Schanz M; Weber J; Uhr T; Rusert P; Trkola A
    PLoS Pathog; 2015 Jul; 11(7):e1004966. PubMed ID: 26158270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing antibodies for HIV-1 prevention.
    Julg B; Barouch DH
    Curr Opin HIV AIDS; 2019 Jul; 14(4):318-324. PubMed ID: 31082819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of neutralizing antibodies in prevention of HIV-1 infection: what can we learn from the mother-to-child transmission context?
    Braibant M; Barin F
    Retrovirology; 2013 Oct; 10():103. PubMed ID: 24099103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo protection by broadly neutralizing HIV antibodies.
    van Gils MJ; Sanders RW
    Trends Microbiol; 2014 Oct; 22(10):550-1. PubMed ID: 25169020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV Reactivation after Partial Protection by Neutralizing Antibodies.
    Parsons MS; Cromer D; Davenport MP; Kent SJ
    Trends Immunol; 2018 May; 39(5):359-366. PubMed ID: 29366547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short Communication: Exploring Antibody Potential as Prophylactic/Therapeutic Strategies for Prevention of Early Mucosal HIV-1 Infection.
    Su B; Peressin M; Ducloy C; Penichon J; Mayr LM; Laumond G; Schmidt S; Decoville T; Moog C
    AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1187-91. PubMed ID: 26252799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.
    Quinnan GV; Yu XF; Lewis MG; Zhang PF; Sutter G; Silvera P; Dong M; Choudhary A; Sarkis PT; Bouma P; Zhang Z; Montefiori DC; Vancott TC; Broder CC
    J Virol; 2005 Mar; 79(6):3358-69. PubMed ID: 15731230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of Fc-mediated functions of anti-HIV-1 broadly neutralizing antibodies.
    Parsons MS; Chung AW; Kent SJ
    Retrovirology; 2018 Aug; 15(1):58. PubMed ID: 30134945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo.
    Rudicell RS; Kwon YD; Ko SY; Pegu A; Louder MK; Georgiev IS; Wu X; Zhu J; Boyington JC; Chen X; Shi W; Yang ZY; Doria-Rose NA; McKee K; O'Dell S; Schmidt SD; Chuang GY; Druz A; Soto C; Yang Y; Zhang B; Zhou T; Todd JP; Lloyd KE; Eudailey J; Roberts KE; Donald BR; Bailer RT; Ledgerwood J; ; Mullikin JC; Shapiro L; Koup RA; Graham BS; Nason MC; Connors M; Haynes BF; Rao SS; Roederer M; Kwong PD; Mascola JR; Nabel GJ
    J Virol; 2014 Nov; 88(21):12669-82. PubMed ID: 25142607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.
    Mascola JR; Stiegler G; VanCott TC; Katinger H; Carpenter CB; Hanson CE; Beary H; Hayes D; Frankel SS; Birx DL; Lewis MG
    Nat Med; 2000 Feb; 6(2):207-10. PubMed ID: 10655111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission.
    Gombos RB; Kolodkin-Gal D; Eslamizar L; Owuor JO; Mazzola E; Gonzalez AM; Korioth-Schmitz B; Gelman RS; Montefiori DC; Haynes BF; Schmitz JE
    J Virol; 2015 Aug; 89(15):7813-28. PubMed ID: 25995259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Trials of Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A Review.
    Mahomed S; Garrett N; Baxter C; Abdool Karim Q; Abdool Karim SS
    J Infect Dis; 2021 Feb; 223(3):370-380. PubMed ID: 32604408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody gene transfer with adeno-associated viral vectors as a method for HIV prevention.
    Brady JM; Baltimore D; Balazs AB
    Immunol Rev; 2017 Jan; 275(1):324-333. PubMed ID: 28133808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity.
    Shapiro MB; Cheever T; Malherbe DC; Pandey S; Reed J; Yang ES; Wang K; Pegu A; Chen X; Siess D; Burke D; Henderson H; Lewinsohn R; Fischer M; Stanton JJ; Axthelm MK; Kahl C; Park B; Lewis AD; Sacha JB; Mascola JR; Hessell AJ; Haigwood NL
    Nat Commun; 2020 Jan; 11(1):70. PubMed ID: 31911610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.
    Shibata R; Igarashi T; Haigwood N; Buckler-White A; Ogert R; Ross W; Willey R; Cho MW; Martin MA
    Nat Med; 1999 Feb; 5(2):204-10. PubMed ID: 9930869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.